Our commitments

Open innovation

Adapt the open innovation R&D model, currently used for Diseases of the Developing World, to apply to other areas of great unmet medical need and scientific challenge, including infectious disease and Alzheimer’s disease, by 2015.

Progress: Complete 

Created the world’s first Open Lab for non-communicable diseases in Africa, which has appointed an independent scientific advisory board as well as selected research projects; accelerating the development of new antibiotics, with our most advanced asset, developed in partnership, moving towards phase III development; taking a collaborative approach to dementia research, supporting scientific partnerships and novel funding mechanisms to accelerate research projects

Close

Building products to better meet needs

Continue to build a core range of products and formats to better meet the needs of people across the globe, including those less able to access and afford our products.

Progress: Progressing well 

Began a clinical trial of a heat-stable, low-cost inhaled form of oxytocin, developed in collaboration with Monash University and other partners. Submitted a regulatory application to the European Medicines Agency (EMA) for an antiseptic gel to prevent umbilical cord infections in newborns, based on the chlorhexidine solution used in our Corsodyl mouthwash.

Close

Better access to medicines and vaccines

Further embed our flexible pricing strategy and innovative business models for our prescription medicines and vaccines, to increase usage among those less able to access and afford our products.

Progress: Progressing well

Partnered with Desano Pharmaceuticals to enable production of our HIV treatment in China and a number of developing countries; extended our price freeze commitment to 10 years for countries ‘graduating’ from Gavi support; as well as pricing all of our six most recently launched new medicines in the US at parity or at a discount to the medicines we aim to supercede.

Close

Reducing child mortality

Continue to invest in innovative cross-sector partnerships to reduce child mortality.

Progress: On track

Through our partnership with Save the Children we have reached over 1.3 million children in the world’s poorest countries. Rewarded sustainable and scalable healthcare innovations to improve under-five child survival rates through our annual $1 million Healthcare Innovation Award.

Close

Strengthening healthcare infrastructure

Continue to work with partners to support the development and strengthening of healthcare infrastructure. We anticipate this could improve access to healthcare for 20 million under-served people by 2020 (vs 2012).

Progress: Progressing well

Continued to re-invest 20% of LDC profits in 35 countries, training an additional 15,000 front-line health workers (40,000 since 2009) and reaching 5.5m people (11 million since 2009). Expanded health worker training beyond LDCs to other countries in sub-Saharan Africa.

Close

Access to antiretroviral treatment for HIV

Through ViiV Healthcare, we will continue to research new treatments, increase access to our medicines and care for people living with HIV around the world. We will support UNAIDS to deliver their 90-90-90 ambition by 2020. We will also work with communities to combat stigma and discrimination associated with HIV.

Progress: Progressing well

Reached 138 countries worldwide through ViiV Healthcare’s access programmes. Granted 16 royalty-free voluntary licences that enable generic manufacturers to sell ViiV Healthcare products at significantly reduced prices. Together with the Clinton Health Access Initiative, enabled pharmaceutical company Aurobindo to file an application to the US FDA for generic approval of dolutegravir.

Close

Fighting malaria

Build on our 30 year commitment to contribute to the fight against malaria through continued R&D investment and partnerships on the ground.

Progress: Progressing well

Received a positive scientific opinion from the European Medicines Agency for our malaria candidate vaccine RTS,S, in children aged six weeks to 17 months. Launched a new £22 million partnership with Comic Relief to fight malaria in five endemic countries.

Close

Eliminating and controlling tropical diseases

Help to eliminate and control ten neglected tropical diseases that affect 1.4 billion people, by 2020 – including the elimination of lymphatic filariasis, through our continued investment in R&D, ongoing product donations and our contribution to the London Declaration on Neglected Tropical Diseases.

Progress: Progressing well

Reached over 760 million people with over 902 million albendazole tablets to eliminate lymphatic filariasis and control intestinal worms. Published data on 600 high-quality hits against neglected tropical diseases in 2015, after screening over two million compounds from our collection.

Close

Eradicating polio

Continue to support the WHO objective of eradicating polio by 2018 by providing vaccines to UNICEF until this is achieved.

Progress: Progressing well

Delivered 220 million doses of oral polio vaccine in 2015, and since 1988, we have contributed over 16 billion doses. Invested in an inactivated polio vaccine facility in Belgium.

Close